Back to top
more

Exact Sciences (EXAS)

(Real Time Quote from BATS)

$47.34 USD

47.34
371,997

+0.29 (0.62%)

Updated Jul 16, 2024 11:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EXAS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Exact Sciences Corporation [EXAS]

Reports for Purchase

Showing records 341 - 360 ( 367 total )

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 341

05/02/2011

Daily Note

Pages: 12

Medical Device Q1 Earnings Preview

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 342

03/30/2011

Company Report

Pages: 5

Preview of Key Upcoming Events

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 343

03/01/2011

Company Report

Pages: 16

Building a Better Screening Test - Initiating with a Buy and $10 Target

Provider: AURIGA USA

Analyst: MEHRA R

Price: 50.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 344

02/16/2011

Company Report

Pages: 5

GEARING UP FOR THE ALL IMPORTANT CLINICAL TRIAL

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 345

02/14/2011

Company Report

Pages: 5

Q4 RESULTS AND CLINICAL TRIAL GUIDENCE

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 346

11/16/2010

Company Report

Pages: 3

Raising Price Target Based On Increased Confidence In The Colon Cancer Test

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 347

11/16/2010

Daily Note

Pages: 11

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 348

10/29/2010

Company Report

Pages: 4

85% SENSITIVITY IN COLORECTAL CANCER; 64% SENSITIVITY IN PRE-CANCERS- BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 349

10/27/2010

Company Report

Pages: 4

Q3 INLINE-AWAITING VALIDATION STUDY DATA-BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 350

10/20/2010

Company Report

Pages: 4

EUROPEAN MARKETING COULD BEGIN IN LATE 2011-BUY.

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 351

10/07/2010

Company Report

Pages: 6

ANTICIPATING STRONG VALIDATION CLINICAL DATA - RAISING PRICE TARGET TO $17

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 352

10/05/2010

Daily Note

Pages: 13

TOP PICKS

Provider: CAPSTONE INVESTMENTS

Price: 50.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 353

09/29/2010

Industry Report

Pages: 4

Life Sciences - Monthly Portfolio Update

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 354

09/22/2010

Industry Report

Pages: 3

Biotechnology - Laboratory Developed Tests Panel Summary

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 355

09/21/2010

Company Report

Pages: 4

CLOSING IN ON TEST VALIDATION- BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 356

08/26/2010

Daily Note

Pages: 21

THE NEXT PERFECT STORM-OBAMACARE WILL STRETCH THE SYSTEM TO ITS ULTIMATE LIMIT

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 75.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 357

07/29/2010

Company Report

Pages: 4

CLINICAL DATA VERY IMPRESSIVE - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 358

07/29/2010

Daily Note

Pages: 6

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 359

07/28/2010

Daily Note

Pages: 3

2Q10 Earnings

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 360

07/27/2010

Industry Report

Pages: 4

Monthly Portfolio Update

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party